Drugs / HS-10380
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05480592 | Aug 2022 → Jun 2023 | schizophrenia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05964790 | Jul 2023 → Jun 2024 | schizophrenia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07550387 | May 2024 → Jan 2026 | schizophrenia 1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10380 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480592 ↗ |
| Route | Oral | “Administered orally as a tablet” NCT05480592 ↗ |